HRP20000380B1 - Oral pharmaceutical extended release dosage form - Google Patents

Oral pharmaceutical extended release dosage form

Info

Publication number
HRP20000380B1
HRP20000380B1 HR20000380A HRP20000380A HRP20000380B1 HR P20000380 B1 HRP20000380 B1 HR P20000380B1 HR 20000380 A HR20000380 A HR 20000380A HR P20000380 A HRP20000380 A HR P20000380A HR P20000380 B1 HRP20000380 B1 HR P20000380B1
Authority
HR
Croatia
Prior art keywords
hydrogen
alkyl
halogen
different
same
Prior art date
Application number
HR20000380A
Other languages
English (en)
Croatian (hr)
Inventor
Karehill Per-Gunnar
Johan Lundberg Per
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20000380A2 publication Critical patent/HRP20000380A2/hr
Publication of HRP20000380B1 publication Critical patent/HRP20000380B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20000380A 1997-12-22 1998-12-17 Oral pharmaceutical extended release dosage form HRP20000380B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9704869A SE9704869D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulaton II
PCT/SE1998/002368 WO1999032091A1 (en) 1997-12-22 1998-12-17 Oral pharmaceutical extended release dosage form

Publications (2)

Publication Number Publication Date
HRP20000380A2 HRP20000380A2 (en) 2001-06-30
HRP20000380B1 true HRP20000380B1 (en) 2007-08-31

Family

ID=20409571

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000380A HRP20000380B1 (en) 1997-12-22 1998-12-17 Oral pharmaceutical extended release dosage form

Country Status (38)

Country Link
US (1) US6605303B1 (enExample)
EP (1) EP1043976B1 (enExample)
JP (1) JP4865945B2 (enExample)
KR (2) KR100755154B1 (enExample)
CN (1) CN1171582C (enExample)
AR (1) AR017201A1 (enExample)
AT (1) ATE312602T1 (enExample)
AU (1) AU759634B2 (enExample)
BG (1) BG65028B1 (enExample)
BR (1) BR9814378A (enExample)
CA (1) CA2315261C (enExample)
CY (1) CY1106072T1 (enExample)
CZ (1) CZ299228B6 (enExample)
DE (1) DE69832816T2 (enExample)
DK (1) DK1043976T3 (enExample)
DZ (1) DZ2685A1 (enExample)
EE (1) EE04901B1 (enExample)
ES (1) ES2252875T3 (enExample)
HR (1) HRP20000380B1 (enExample)
HU (1) HUP0101437A3 (enExample)
IL (2) IL136827A0 (enExample)
IS (1) IS5524A (enExample)
MA (1) MA26576A1 (enExample)
MY (1) MY126555A (enExample)
NO (1) NO20003218L (enExample)
NZ (1) NZ505127A (enExample)
PL (1) PL193776B1 (enExample)
RU (1) RU2214232C2 (enExample)
SA (1) SA99191077B1 (enExample)
SE (1) SE9704869D0 (enExample)
SK (1) SK284988B6 (enExample)
TN (1) TNSN98229A1 (enExample)
TR (1) TR200001981T2 (enExample)
TW (1) TWI249410B (enExample)
UA (1) UA69397C2 (enExample)
WO (1) WO1999032091A1 (enExample)
YU (1) YU36700A (enExample)
ZA (1) ZA9811239B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207198B1 (en) * 1995-09-21 2001-03-27 Schwarz Pharma Ag Composition containing an acid-labile omeprazole and process for its preparation
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
WO1999029299A1 (en) 1997-12-08 1999-06-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel suppository form comprising an acid-labile active compound
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
PT1341528E (pt) * 2000-12-07 2012-03-20 Nycomed Gmbh Comprimido de desintegração rápida compreendendo um ingrediente activo lábil a ácido
JP4848101B2 (ja) * 2001-08-17 2011-12-28 株式会社フジモト・コーポレーション 徐放性マイクロペレット
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
MXPA05003162A (es) 2002-09-26 2005-07-05 Yamanouchi Pharma Co Ltd Agentes mejoradores de absorbibilidad de droga.
JP4493970B2 (ja) * 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US8697094B2 (en) 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
EP1607088B1 (en) 2003-03-17 2019-02-27 Takeda Pharmaceutical Company Limited Controlled release composition
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
WO2005012289A1 (en) * 2003-07-17 2005-02-10 Altana Pharma Ag Novel salt of (r) - pantoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
FR2861990B1 (fr) * 2003-11-10 2006-02-10 Nouveaux Produits Pharma Comprimes faiblement doses a reseau de polymeres
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2469427A1 (en) * 2004-06-01 2005-12-01 Pharmascience Inc. Dry mixed dosage form containing benzimidazole derivatives
WO2006009602A2 (en) 2004-06-16 2006-01-26 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
US20090124702A1 (en) * 2005-01-25 2009-05-14 Pechetti Siva Satya Krishna Babu Pharmaceutical Compositions of Metformin
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
DE102005060393A1 (de) * 2005-12-16 2007-06-21 Add Advanced Drug Delivery Technologies Ltd. Orales Präparat mit kontrollierter Freisetzung
SG184754A1 (en) * 2005-12-28 2012-10-30 Takeda Pharmaceutical Controlled release solid preparation
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US20080181932A1 (en) * 2007-01-30 2008-07-31 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
US8679541B2 (en) * 2007-03-14 2014-03-25 Particle Dynamics International, Llc Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals
CA2702356C (en) * 2007-10-12 2014-02-11 Takeda Pharmaceuticals North America, Inc. Pharmaceutical formulation comprising a proton pump inhibitor for the treatment of gastrointestinal conditions independent of food intake
US12011423B2 (en) 2007-11-06 2024-06-18 Foraviset Ltd. S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
JP5592902B2 (ja) 2009-03-09 2014-09-17 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 治療薬の徐放性組成物
US20140127296A1 (en) * 2012-11-05 2014-05-08 Kenneth John Tibbs Pharmaceutical preparation and method for treatment of diabetes
AU2014216373B2 (en) * 2013-02-13 2017-12-21 Red Hill Biopharma, Ltd Pharmaceutical compositions for the treatment of Helicobacter pylori
CN104721185A (zh) * 2013-12-21 2015-06-24 辰欣药业股份有限公司 一种提高埃索美拉唑钠稳定性的方法
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10729735B1 (en) 2016-09-14 2020-08-04 Phoenix Biotechnology, Inc. Method and compostitions for treating coronavirus infection
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
AU4640985A (en) * 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US5229181A (en) * 1990-10-30 1993-07-20 Amber Technologies Tubular knit cleanroom wiper
TW209174B (enExample) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
IT1251153B (it) 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
US5178867A (en) * 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
ES2179829T3 (es) * 1992-09-18 2003-02-01 Yamanouchi Pharma Co Ltd Preparacion de hidrogel de liberacion prolongada.
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
JPH07330629A (ja) * 1994-06-02 1995-12-19 Nippon Shokubai Co Ltd 徐放性製剤
DE69535889D1 (de) * 1994-07-08 2009-01-02 Astrazeneca Ab Aus vielen Einzeleinheiten zusammengesetzte tablettierte Dosisform
SK281803B6 (sk) * 1994-07-08 2001-08-06 Astra Ab Orálny entericky potiahnutý prípravok, ktorý obsahuje magnéziovú soľ omeprazolu, a spôsob jeho výroby
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US7016717B2 (en) * 2002-07-05 2006-03-21 The Regents Of The University Of California Near-infrared spectroscopic tissue imaging for medical applications
ITPD20050230A1 (it) * 2005-07-28 2007-01-29 Marcato Spa Macchina ad uso domestico per la estrusione di paste alimentari fresche

Also Published As

Publication number Publication date
US6605303B1 (en) 2003-08-12
MA26576A1 (fr) 2004-12-20
KR100755154B1 (ko) 2007-09-04
EP1043976B1 (en) 2005-12-14
NO20003218L (no) 2000-08-22
KR20010033428A (ko) 2001-04-25
HRP20000380A2 (en) 2001-06-30
HUP0101437A2 (hu) 2001-10-28
CA2315261C (en) 2008-02-12
ES2252875T3 (es) 2006-05-16
BR9814378A (pt) 2000-10-10
SE9704869D0 (sv) 1997-12-22
HK1034455A1 (en) 2001-10-26
MY126555A (en) 2006-10-31
DK1043976T3 (da) 2006-03-20
KR20060097069A (ko) 2006-09-13
CZ20002314A3 (cs) 2000-11-15
CZ299228B6 (cs) 2008-05-21
JP2001526211A (ja) 2001-12-18
NO20003218D0 (no) 2000-06-21
IL136827A0 (en) 2001-06-14
BG104620A (en) 2001-04-30
NZ505127A (en) 2003-02-28
CA2315261A1 (en) 1999-07-01
PL341428A1 (en) 2001-04-09
AU1991299A (en) 1999-07-12
AR017201A1 (es) 2001-08-22
DE69832816T2 (de) 2006-08-31
PL193776B1 (pl) 2007-03-30
AU759634B2 (en) 2003-04-17
CN1284866A (zh) 2001-02-21
CN1171582C (zh) 2004-10-20
DE69832816D1 (de) 2006-01-19
HUP0101437A3 (en) 2003-01-28
TNSN98229A1 (fr) 2005-03-15
WO1999032091A1 (en) 1999-07-01
RU2214232C2 (ru) 2003-10-20
ZA9811239B (en) 1999-06-22
SK8072000A3 (en) 2001-01-18
BG65028B1 (bg) 2006-12-29
EP1043976A1 (en) 2000-10-18
ATE312602T1 (de) 2005-12-15
DZ2685A1 (fr) 2003-03-29
UA69397C2 (uk) 2004-09-15
EE200000383A (et) 2001-12-17
EE04901B1 (et) 2007-10-15
YU36700A (sh) 2003-01-31
TR200001981T2 (tr) 2000-11-21
JP4865945B2 (ja) 2012-02-01
TWI249410B (en) 2006-02-21
SA99191077B1 (ar) 2006-07-11
SK284988B6 (sk) 2006-04-06
CY1106072T1 (el) 2011-06-08
IS5524A (is) 2000-06-08
IL136827A (en) 2007-05-15

Similar Documents

Publication Publication Date Title
HRP20000380B1 (en) Oral pharmaceutical extended release dosage form
YU49475B (sh) Postupak za sintezu supstituisanih sulfoksida
PE20010992A1 (es) Formulacion de liberacion sostenida de un inhibidor de ciclooxigenasa-2
TR200002681T2 (tr) 2-(2,6-Dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı
PE20040512A1 (es) Compuesto de pirazol-pirimidina anilina
PT795025E (pt) Preparacao enantiosselectiva de sulfoxidos farmaceuticamente aceitaveis por bio-reducao
GEP20074148B (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
SI1070056T1 (en) Phthalazinone pde iii/iv inhibitors
HUP0201659A2 (hu) Kristályos benzimidazol-vegyület
DK0869947T3 (da) Barbitursyrederivater, fremgangsmåder til fremstilling deraf og farmaceutiske midler, der indeholder disse forbindelser
ATE72436T1 (de) 2-(methyl(4-piperidinyl)>-1,2,3,4-tetrahydro-9h pyrido(3,4-b>indolderivate, ihre herstellung und therapeutische verwendung.
MXPA02005604A (es) Aminobenzofenonas como inhibidores de il-1beta y tnf-alfa.
DK0941221T3 (da) Substituerede dihydrobenzofuraner som PDE-inhibitorer
NZ332990A (en) oral pharmaceutical composition containing a H+, K+-atpase inhibitor having a extended blood plasma profile
ATE305787T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
EP0794780A4 (en) Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
DE60213087D1 (de) Pyrimidin-derivate als selektive inhibitoren von cox-2
IL132575A0 (en) Benzimidazole derivative
ATE234818T1 (de) Chinolinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE167855T1 (de) Propensäure derivate verwendbar als fungizide
ATE257833T1 (de) 2-arylalkylthio -imidazole, 2-arylalkenyl -thio - imidazole und 2-arylalkinyl -thio -imidazole als entzündungs -hemmstoffe und hemmstoffe der cytokin -freisetzung
AR014626A1 (es) Piridino arilpiperazinas sustituidas utiles en el tratamiento de hiperplasia prostatica benigna, una composicion farmaceutica que las comprende y el uso de las mismas para la fabricacion de un medicamento.
ATE191465T1 (de) Carbamoylcarbonsäureamide
ATE172724T1 (de) Anthelmintische benzimidazole
DK0687257T3 (da) 4-amino-2-(hetero)aryl-butanamider anvendelige som 5HT1A-antagonister

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20071024

Year of fee payment: 10

PBON Lapse due to non-payment of renewal fee

Effective date: 20081218